Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS).

Diabetes Ther · 2022 · PMC8989913 · PMID 35258841

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Oral semaglutide showed a clear trend towards reducing the risk of MACE, by 21%, which was statistically nonsignificant compared to 26% for injectable semaglutide, both versus placebo [ 39 ].

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.